皮脂增生:一例报告并文献复习。

HCA healthcare journal of medicine Pub Date : 2023-08-29 eCollection Date: 2023-01-01 DOI:10.36518/2689-0216.1524
Carsten Z Steinmetz, Amanda Getz, Andras Schaffer, Stephen K Richardson
{"title":"皮脂增生:一例报告并文献复习。","authors":"Carsten Z Steinmetz,&nbsp;Amanda Getz,&nbsp;Andras Schaffer,&nbsp;Stephen K Richardson","doi":"10.36518/2689-0216.1524","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Eruptive sebaceous hyperplasia (ESH) is a benign process characterized by the acute onset and rapid proliferation of sebaceous glands, typically on the face. Although historically attributed to cyclosporine therapy, the preponderance of reports over the past 2 decades suggests a more complex etiology. There is increasing thought a combination of multiple medications as well as a genetic component contribute to ESH's clinical presentation. Despite these theories, the exact cause of ESH in immunosuppressive therapy is poorly understood.</p><p><strong>Case presentation: </strong>To our knowledge, we report the third case of ESH arising in multimodality immunosuppressive therapy, consisting of tacrolimus, mycophenolate mofetil, and prednisone, affecting a renal transplant patient. Our patient began cyclosporine monotherapy at an early age but did not see eruption of lesions until years later after following a multimodal therapy.</p><p><strong>Conclusion: </strong>We discuss the association of ESH with other medical conditions and treatments. We hope this case sheds light on a possible complication of multimodal immunosuppressive therapy in renal transplant patients. This will allow patients and providers to be better informed of the pros and cons of different treatment options for immunosuppressive therapy in renal transplant patients.</p>","PeriodicalId":73198,"journal":{"name":"HCA healthcare journal of medicine","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10519630/pdf/26890216_vol4_iss4_315.pdf","citationCount":"0","resultStr":"{\"title\":\"Eruptive Sebaceous Hyperplasia: A Case Report and Review of the Literature.\",\"authors\":\"Carsten Z Steinmetz,&nbsp;Amanda Getz,&nbsp;Andras Schaffer,&nbsp;Stephen K Richardson\",\"doi\":\"10.36518/2689-0216.1524\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Eruptive sebaceous hyperplasia (ESH) is a benign process characterized by the acute onset and rapid proliferation of sebaceous glands, typically on the face. Although historically attributed to cyclosporine therapy, the preponderance of reports over the past 2 decades suggests a more complex etiology. There is increasing thought a combination of multiple medications as well as a genetic component contribute to ESH's clinical presentation. Despite these theories, the exact cause of ESH in immunosuppressive therapy is poorly understood.</p><p><strong>Case presentation: </strong>To our knowledge, we report the third case of ESH arising in multimodality immunosuppressive therapy, consisting of tacrolimus, mycophenolate mofetil, and prednisone, affecting a renal transplant patient. Our patient began cyclosporine monotherapy at an early age but did not see eruption of lesions until years later after following a multimodal therapy.</p><p><strong>Conclusion: </strong>We discuss the association of ESH with other medical conditions and treatments. We hope this case sheds light on a possible complication of multimodal immunosuppressive therapy in renal transplant patients. This will allow patients and providers to be better informed of the pros and cons of different treatment options for immunosuppressive therapy in renal transplant patients.</p>\",\"PeriodicalId\":73198,\"journal\":{\"name\":\"HCA healthcare journal of medicine\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-08-29\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10519630/pdf/26890216_vol4_iss4_315.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"HCA healthcare journal of medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.36518/2689-0216.1524\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2023/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"HCA healthcare journal of medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.36518/2689-0216.1524","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

简介:皮脂腺增生(ESH)是一种良性过程,其特征是皮脂腺的急性发作和快速增殖,通常发生在面部。尽管在历史上被认为是环孢菌素治疗,但在过去20年中的大量报道表明其病因更为复杂。越来越多的人认为多种药物的组合以及遗传成分有助于ESH的临床表现。尽管有这些理论,但免疫抑制治疗中ESH的确切原因尚不清楚。病例介绍:据我们所知,我们报告了第三例由他克莫司、霉酚酸酯和泼尼松组成的多模式免疫抑制治疗引起的ESH,影响了一名肾移植患者。我们的患者在很小的时候就开始了环孢菌素单药治疗,但直到多年后接受多模式治疗后才出现病变。结论:我们讨论了ESH与其他疾病和治疗的关系。我们希望这个病例能揭示肾移植患者多模式免疫抑制治疗可能出现的并发症。这将使患者和提供者更好地了解肾移植患者免疫抑制治疗的不同治疗方案的优缺点。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Eruptive Sebaceous Hyperplasia: A Case Report and Review of the Literature.

Introduction: Eruptive sebaceous hyperplasia (ESH) is a benign process characterized by the acute onset and rapid proliferation of sebaceous glands, typically on the face. Although historically attributed to cyclosporine therapy, the preponderance of reports over the past 2 decades suggests a more complex etiology. There is increasing thought a combination of multiple medications as well as a genetic component contribute to ESH's clinical presentation. Despite these theories, the exact cause of ESH in immunosuppressive therapy is poorly understood.

Case presentation: To our knowledge, we report the third case of ESH arising in multimodality immunosuppressive therapy, consisting of tacrolimus, mycophenolate mofetil, and prednisone, affecting a renal transplant patient. Our patient began cyclosporine monotherapy at an early age but did not see eruption of lesions until years later after following a multimodal therapy.

Conclusion: We discuss the association of ESH with other medical conditions and treatments. We hope this case sheds light on a possible complication of multimodal immunosuppressive therapy in renal transplant patients. This will allow patients and providers to be better informed of the pros and cons of different treatment options for immunosuppressive therapy in renal transplant patients.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信